Events

EDGE Business Connection

On May 19th, 2015, EDGE Business Connection: Resources to Grow Minority-Owned, Women-Owned and other Small Businesses was held at the Innovation Center, Ohio University.

As its name “EDGE” suggests, the State of Ohio’s EDGE program provides an EDGE to small businesses by Encouraging Diversity, Growth and Equity in public contracting. EDGE is a program for economically and socially disadvantaged business enterprises. The State of Ohio developed the program because it is committed to making all state contracts, services, benefits, and opportunities available without discriminating on the basis of race, color, religion, sex, national origin, disability, age or ancestry. Yanrong Qian, a postdoc and economic development assistant at EBI, Ohio University, attended this event on behalf of Edison Biotechnology Institute.

Photo: Yanrong Qian and Gregory L. Williams, Deputy Director/State EEO Coordinator, Equal Opportunity Division, Ohio Department of Administrative Services.

Save the Dates

✧ The Fourth Appalachian Regional Cell Conference
✧ November 21, 2015 • Huntington, WV

✧ The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival
✧ September 16-19, 2015 • Sheraton New York Times Square Hotel • New York, NY

✧ Translational Cancer Research for Basic Scientists Workshop
✧ November 8-13, 2015 • Omni Parker House Hotel • Boston, MA
Dr. Haotong Chen, Postdoctoral Researcher

Haotong Chen is from China. When she came to the U.S. in 2009, she joined Dr. Liangcheng Du's group at the University of Nebraska - Lincoln. She earned her PhD in Chemistry this year and will be continuing her career as a postdoctoral fellow at EBI. She is actively engaged in the study of novel natural product discovery, preparation, biosynthetic mechanism study and genetic engineering. She will be joining Edison Biotechnology Institute July, 2015. Welcome, Dr. Haotong Chen!

Dr. Shinhee Lee, Research Scientist I

Shinhee Lee is a research scientist I at EBI. She received her Ph.D. from Korea University in Seoul, Korea (2009) and has been working in Dr. Wu’s lab. Her research interests are to understand the cellular and molecular mechanisms triggered by radiation (IR and UV), with a primary focus on DNA damage signaling pathway and cell motility. These are implicated in cancer progression and metastasis, therefore the main goals of her research cover cancer cellular biology and therapies for cancer and the development of targeted therapies for both the advanced and early stages of cancer.

Dr. Hyun Young Park, Postdoctoral Researcher

Dr. Hyun Young Park studied Biochemistry at the College of Natural Sciences at Kangwon National University in South Korea where she also studied Pharmacognosy in the College of Pharmacy. After she received her Master’s degree in Pharmacognosy, she went to Japan for her PhD program in the Graduate School of Pharmaceutical Science, Chiba University, Japan, as a Japanese government scholarship student. During her PhD studies, she has been working in searching bioactive natural products for new cancer treatments under the supervision of Professor Masami Ishibashi. She then received her PhD in 2014 and is currently working as post-doctoral researcher in the Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, the Ohio State University, Columbus OH. Her ongoing project is focusing on the discovery of novel compounds from endophytic fungi that have potential activities of anti-malarial or anti-cancer. The main interest of her research is to find new biologically active natural products to develop dietary supplements or drug leads. She will be joining Edison Biotechnology Institute in August, 2015. Welcome, Dr. Hyun Young Park!
Cancer cells drink Red Bull

Cancer cells drink extracellular ATP in intratumoral spaces to support their rapid growth and survival, and to promote drug resistance. See more at: http://www.sciencedirect.com/science/article/pii/S0304383514003139 Video available.


Gold Standard for liver toxicity

A particularly useful set of compounds was selected to support the development of in vitro systems for the identification of hepatotoxic compounds, with reviewing their known mechanisms of action. See more at: http://link.springer.com/article/10.1007%2Fs00204-014-1410-8


microRNAs targeting NF-kappa B signaling for cancer treatment

NF-κB-targeting miRNAs have been identified and characterized as potential therapeutics for cancer treatment and sensitizers of chemo and radiotherapies. See more mechanism and therapeutic use of NF-κB-targeting miRNA for cancer treatment at: http://www.sciencedirect.com/science/article/pii/S0169409X14002026.


GH/IGF-1 axis in aging and longevity

Medical disruption of the GH/IGF-1 axis in humans may increase longevity and the therapeutic benefits. See more at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074016/

Growth hormone and hypertension

Elevated systolic blood pressure in male growth hormone transgenic mice is dependent on age, independent of insulin resistance, and related to alterations in both the natriuretic peptide and renin-angiotensin systems. See more at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929738/
